Virtu Financial LLC Acquires New Position in Catalent, Inc. (NYSE:CTLT)

Virtu Financial LLC acquired a new position in shares of Catalent, Inc. (NYSE:CTLT) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,624 shares of the company’s stock, valued at approximately $432,000.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Catalent by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after purchasing an additional 365,648 shares during the last quarter. Tran Capital Management L.P. grew its holdings in Catalent by 12.2% in the 4th quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after buying an additional 39,208 shares in the last quarter. Hsbc Holdings PLC increased its position in Catalent by 43.1% in the 3rd quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock valued at $8,803,000 after acquiring an additional 58,240 shares during the period. Dimensional Fund Advisors LP raised its stake in Catalent by 29.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company’s stock valued at $73,655,000 after acquiring an additional 376,931 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Catalent by 240.0% during the 4th quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after acquiring an additional 28,410 shares during the period.

Catalent Trading Down 0.3 %

NYSE:CTLT opened at $55.07 on Wednesday. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $60.20. The stock has a fifty day simple moving average of $55.59 and a 200 day simple moving average of $52.96. The firm has a market capitalization of $9.97 billion, a price-to-earnings ratio of -9.03, a price-to-earnings-growth ratio of 6.67 and a beta of 1.20. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. Sell-side analysts forecast that Catalent, Inc. will post 0.28 earnings per share for the current year.

Insider Activity at Catalent

In other news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the transaction, the insider now owns 20,617 shares in the company, valued at approximately $1,118,678.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.31% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on CTLT shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. StockNews.com started coverage on shares of Catalent in a research note on Friday, June 14th. They issued a “sell” rating for the company. Finally, Stephens reiterated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $54.05.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.